The San Francisco Bay Area has experienced a particularly intense HIV epidemic, with men who have sex with men (MSM), Black, and Latino populations most heavily impacted in the region. Drs. Susan Buchbinder and Diane Havlir are scientific leaders in HIV prevention and treatment, respectively. Together they will form the San Francisco Bay Area Clinical Trials Unit (SFBay CTU), affiliated with the HVTN, HPTN, MTN, and ACTG. This integrated research organization will accomplish 3 specific aims through these Networks: 1) advance prevention and treatment science and their intersection through scientific leadership;2) implement clinical trials efficiently and with excellent adherence to protocol while engaging diverse communities;and 3) develop a new generation of diverse leaders in HIV prevention and treatment science. Drs. Buchbinder and Havlir are joined by a diverse pool of talented investigators who have provided leadership across the Networks, serving on numerous scientific leadership committees and working groups and chairing a range of prevention and treatment protocols. The 3 Clinical Research Sites (Bridge HIV led by Buchbinder, UCSF led by Havlir, and Stanford led by Zolopa) all have a record of excellence in enrollment, retention, and adherence to protocol requirements, and actively engage local communities in their research.

Public Health Relevance

The newly formed San Francisco Bay Clinical Trials Unit will conduct HIV vaccine, prevention and treatment trials in San Francisco, Oakland, San Jose, and their surrounding communities. By bringing together leading scientists and a diverse community in the San Francisco Bay Area, this new research unit will develop ways to prevent and treat HIV infections and work towards an effective HIV vaccine and cure.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-UKS-A (S1))
Program Officer
Jones, Patricia L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Public Health Foundation Enterprises
City of Industry
United States
Zip Code
Kadede, Kevin; Ruel, Theodore; Kabami, Jane et al. (2016) Increased adolescent HIV testing with a hybrid mobile strategy in Uganda and Kenya. AIDS 30:2121-6
Godfrey, Catherine; Tauscher, Gail; Hunsberger, Sally et al. (2016) A survey of tuberculosis infection control practices at the NIH/NIAID/DAIDS-supported clinical trial sites in low and middle income countries. BMC Infect Dis 16:269
Huang, Ying; DiazGranados, Carlos; Janes, Holly et al. (2016) Selection of HIV vaccine candidates for concurrent testing in an efficacy trial. Curr Opin Virol 17:57-65
Lee, Sulggi A; Mefford, Joel A; Huang, Yong et al. (2016) Host genetic predictors of the kynurenine pathway of tryptophan catabolism among treated HIV-infected Ugandans. AIDS 30:1807-15
Cohen, Myron S; Chen, Ying Q; McCauley, Marybeth et al. (2016) Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med 375:830-9
Saharia, Kapil K; Petrovas, Constantinos; Ferrando-Martinez, Sara et al. (2016) Tuberculosis Therapy Modifies the Cytokine Profile, Maturation State, and Expression of Inhibitory Molecules on Mycobacterium tuberculosis-Specific CD4+ T-Cells. PLoS One 11:e0158262
Nelson, LaRon E; Wilton, Leo; Moineddin, Rahim et al. (2016) Economic, Legal, and Social Hardships Associated with HIV Risk among Black Men who have Sex with Men in Six US Cities. J Urban Health 93:170-88
Zheng, Jia-Hua; Rower, Caitlin; McAllister, Kevin et al. (2016) Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots. J Pharm Biomed Anal 122:16-20
Landovitz, Raphael J; Tran, Thuy Tien T; Cohn, Susan E et al. (2016) HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States. AIDS Behav 20:2983-2995
Glidden, David V; Amico, K Rivet; Liu, Albert Y et al. (2016) Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension. Clin Infect Dis 62:1172-7

Showing the most recent 10 out of 92 publications